openPR Logo
Press release

Anaplastic Large Cell Lymphoma (ALCL) Therapeutics Market Size will Observe Lucrative Surge by the End 2026

08-14-2018 12:14 PM CET | Health & Medicine

Press release from: Future Market Insights

Anaplastic Large Cell Lymphoma (ALCL) Therapeutics Market Size

Lymphoma is the most common type of blood cancer that affects that develops in the lymphatic system. Lymphoma are of two major types: Hodgkin lymphoma and non-Hodgkin lymphoma (NHL). Lymphoma is caused when lymphocytes, type of white blood cells of the immune system grow and multiply uncontrollably. Cancerous lymphocytes may travel to different parts of the body, including the spleen, blood, lymph nodes, bone marrow, and form a mass called a tumor. The two type of lymphocytes that can develop into lymphoma – B-lymphocytes (B-cells) and T-lymphocytes (T-cells). Anaplastic large cell lymphoma (ALCL) is a rare type of non-Hodgkin lymphoma and a common subtype of T-cell lymphoma. ALCL consists of only 2% of NHLs and approx. 20% of T-cell lymphomas. ALCL symptoms includes fever, painless swelling of lymph nodes, weight loss, tiredness, backache and excessive night sweats. It is comprised of two sub-types, based on the expression of a protein called anaplastic lymphoma kinase (ALK): ALK positive and ALK negative ALCL

A sample of this report is available upon request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1655

According to National Cancer Institute, in the 2016, an estimated 1,685,210 new cases of cancer will be diagnosed in the United States and 595,690 people will die from the disease. NHL is the sixth most commonly diagnosed cancer in both men and women in the US. In 2015, it is estimated that there will be 71,850 new cases of NHL (39,850 men and 32,000 women) and 19,790 deaths from NHL. According to GLOBOCAN 2012 estimates the incidence and mortality rate of NHL is 2.7% and 2.4% respectively.

Following drugs are being tested for ALCL:

Alisertib (MLN8237)

Bortezomib (Velcade)

Combination of brentuximab vedotin and chemotherapy

Crizotinib (Xalkori)

The global ALCL therapeutics market is segmented on the basis of route of administration, therapeutic areas and region

Segmentation based on Disease Type

Primary ALCL

Relapsed ALCL

Segmentation based on Treatment Type

Chemotherapy

(CHOP) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

Brentuximab vedotin

Pralatrexate

Surgery

Radiation therapy

Stem cell transplant

With the increasing geriatric population and rate of diagnosis will boost the overall market for ALCL therapeutics. Moreover, significant increase in the healthcare spending will boost the ALCL therapeutics market during the forecast period.

Geographically the ALCL therapeutics market is segmented into five key regions: North America, Latin America, Europe, Asia Pacific and MEA region. The areas with the highest incidence of NHL are North America, Europe, and Australasia, as well as several countries in Africa and South America. Also, more than 60% of the world’s new cancer cases occur in Africa, Asia, and Central and South America; 70% of the world’s cancer deaths occur in these regions.

The ALCL can appear on body parts such as skin, organs and other part of the body, they grow slowly and are present on body for longer duration before diagnosis. ALCL that appears on skin is known as primary cutaneous ALCL. Most common types of side effects observed are skin redness and skin irritation is caused. It is being observed that 10 percent primary cutaneous ALCL extends beyond the skin to organ or lymph. Systemic ALCL is parted depending on abnormal form of a protein on their surface called ALK or do not have abnormal form of a protein. These are fast growing and the disease condition in ALK-positive (with abnormal protein) is different from ALK-negative (without abnormal protein). ALK-positive ALCL patients are treated with chemotherapy treatments, patients initially respond to the treatment but relapse within five years, these are found in children’s as well as adults. ALK-negative ALCL patients are treated with stem cell transplantation after remission, these are mostly found in patients above 55 years.

To view TOC of this report is available upon request @ https://www.futuremarketinsights.com/toc/rep-gb-1655

Some major companies in the ALCL therapeutics market are Pfizer, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Seattle Genetics, Inc., Sareum Holdings PLC, Merck Sharp & Dohme Corp., Celgene Corporation and Valeant Pharmaceuticals North America LLC.

About Us
Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centres in the U.S. and India.

FMI’s research and consulting services help businesses around the globe navigate the challenges in a rapidly evolving marketplace with confidence and clarity. Our customised and syndicated market research reports deliver actionable insights that drive sustainable growth. We continuously track emerging trends and events in a broad range of end industries to ensure our clients prepare for the evolving needs of their consumers.

Contact Us
U.S. Office
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
Email: sales@futuremarketinsights.com
Web:https://www.futuremarketinsights.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Anaplastic Large Cell Lymphoma (ALCL) Therapeutics Market Size will Observe Lucrative Surge by the End 2026 here

News-ID: 1179180 • Views:

More Releases from Future Market Insights

Aerospace Fluid Conveyance System Market to Reach USD 4.3 Billion by 2035 with Innovative Components and Growth
Aerospace Fluid Conveyance System Market to Reach USD 4.3 Billion by 2035 with I …
The global Aerospace Fluid Conveyance System Market is witnessing steady growth, driven by the increasing demand for advanced fluid handling solutions across commercial and military aircraft. Valued at USD 3.1 billion in 2025, the market is projected to reach USD 4.3 billion by 2035, registering a healthy CAGR of 3.4%. Both established and emerging manufacturers are actively innovating to meet the evolving needs of the aviation sector. Market Dynamics and Growth
Automotive Starter and Alternator Market to Reach USD 45.4 Billion by 2035 Amid Electrification Trends
Automotive Starter and Alternator Market to Reach USD 45.4 Billion by 2035 Amid …
The global Automotive Starter and Alternator Market is on track for substantial expansion, driven by rapid advancements in vehicle technology and the growing focus on electrification. Valued at USD 29.3 billion in 2025, the market is projected to reach USD 45.4 billion by 2035, registering a CAGR of 4.5% during the forecast period. The growth reflects the automotive industry's continuous evolution toward fuel-efficient and sustainable systems that integrate reliability, performance,
Connected Aircraft Market Soars to USD 63.6 Billion by 2035, Driven by Connectivity and Digital Innovation
Connected Aircraft Market Soars to USD 63.6 Billion by 2035, Driven by Connectiv …
The global Connected Aircraft Market is poised for transformative growth, projected to rise from USD 6.8 billion in 2025 to USD 63.6 billion by 2035, registering an impressive CAGR of 25.1% over the forecast period. This surge is being fueled by airlines' growing focus on enhancing operational efficiency, passenger experience, and safety through advanced connectivity solutions. Industry leaders such as Honeywell International Inc., Thales Group, Raytheon Technologies Corporation, BAE Systems PLC,
Slingshot/3-Wheeled Motorcycle Market Set to Hit USD 1.8 Billion by 2035 Driven by Design and Innovation
Slingshot/3-Wheeled Motorcycle Market Set to Hit USD 1.8 Billion by 2035 Driven …
The global Slingshot/3-Wheeled Motorcycle Market is on track to witness sustained growth, driven by shifting consumer lifestyles, urban mobility trends, and a rising interest in alternative transportation. Valued at USD 1.3 billion in 2025, the market is projected to reach USD 1.8 billion by 2035, expanding at a CAGR of 2.9%. During the early growth phase (2021-2025), the market experiences gradual expansion, fueled by consumers' growing appetite for distinctive vehicles that

All 5 Releases


More Releases for ALCL

Anaplastic Large Cell Lymphoma (ALCL) Market New Product Development & Latest Tr …
Introduction Anaplastic large cell lymphoma (ALCL) is a rare and aggressive subtype of non-Hodgkin's lymphoma (NHL) that arises from T-cells. ALCL accounts for a small proportion of lymphomas but is clinically significant due to its aggressive nature and the availability of unique therapeutic pathways, such as targeting the anaplastic lymphoma kinase (ALK) protein in ALK-positive cases. Over the past decade, major breakthroughs in targeted therapies, monoclonal antibodies, and immunotherapy have transformed the
Anaplastic Large Cell Lymphoma (ALCL) Therapeutics Market Segments and Key Trend …
Lymphoma is the most common type of blood cancer that affects that develops in the lymphatic system. Lymphoma are of two major types: Hodgkin lymphoma and non-Hodgkin lymphoma (NHL). Lymphoma is caused when lymphocytes, type of white blood cells of the immune system grow and multiply uncontrollably. Cancerous lymphocytes may travel to different parts of the body, including the spleen, blood, lymph nodes, bone marrow, and form a mass called
Anaplastic Large Cell Lymphoma (ALCL) Therapeutics Market to Gain a Stronghold b …
Lymphoma is the most common type of blood cancer that affects that develops in the lymphatic system. Lymphoma are of two major types: Hodgkin lymphoma and non-Hodgkin lymphoma (NHL). Lymphoma is caused when lymphocytes, type of white blood cells of the immune system grow and multiply uncontrollably. Cancerous lymphocytes may travel to different parts of the body, including the spleen, blood, lymph nodes, bone marrow, and form a mass called
Global Anaplastic Large Cell Lymphoma (ALCL) Clinical Trials Industry Analysis a …
Market Research Hub's clinical trial report, Global Anaplastic Large Cell Lymphoma (ALCL) Clinical Trials Review, H1, 2017, provides an overview of Anaplastic Large Cell Lymphoma (ALCL) clinical trials scenario. This report provides top line data relating to the clinical trials on Anaplastic Large Cell Lymphoma (ALCL). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Request Free Sample Report@ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1068380 Report offers coverage
Anaplastic Large Cell Lymphoma (ALCL) Therapeutics Market Dynamics, Forecast, An …
Lymphoma is the most common type of blood cancer that affects that develops in the lymphatic system. Lymphoma are of two major types: Hodgkin lymphoma and non-Hodgkin lymphoma (NHL). Lymphoma is caused when lymphocytes, type of white blood cells of the immune system grow and multiply uncontrollably. Cancerous lymphocytes may travel to different parts of the body, including the spleen, blood, lymph nodes, bone marrow, and form a mass called
Anaplastic Large Cell Lymphoma (ALCL) Therapeutics Market Globally Expected to D …
Lymphoma is the most common type of blood cancer that affects that develops in the lymphatic system. Lymphoma are of two major types: Hodgkin lymphoma and non-Hodgkin lymphoma (NHL). Lymphoma is caused when lymphocytes, type of white blood cells of the immune system grow and multiply uncontrollably. Cancerous lymphocytes may travel to different parts of the body, including the spleen, blood, lymph nodes, bone marrow, and form a mass called